Health care; creating the Hope for Oklahoma Patients Act; authorizing individualized investigational treatments for eligible patients. Effective date.

SB 1844, the "Hope for Oklahoma Patients Act," allows eligible Oklahoma patients with life-threatening or severely debilitating conditions to access genetically tailored investigational treatments (like personalized gene therapies or vaccines) when all FDA-approved options have been exhausted. It defines "eligible patients" as those meeting strict medical criteria, including physician attestation and written consent, and requires treatments to be based on the patient’s unique genetic profile. The bill makes participation voluntary for healthcare facilities and manufacturers (who may choose not to provide treatments), requires patients to cover manufacturing costs, and clarifies that insurers and government entities are not obligated to cover these treatments. It explicitly excludes treatments derived from embryonic stem cells or abortion-related materials and prohibits state entities from interfering with provider discretion.